Oncology

The trial data showed ongoing clinical benefit in patients with advanced endometrial cancer who completed pembrolizumab and continued on lenvatinib vs chemotherapy alone.

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

This is the first phase 3 trial to evaluate a KRAS G12C-inhibitor plus an anti-epidermal growth factor receptor antibody for this type of colorectal cancer.

The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.

Oncology leaders and pharma representatives discuss collaboration best practices.

Not only did taletrectinib shrink tumors in 92% of patients who were tyrosine kinase inhibitor -naïve, but 89.5% of patients continued to respond to treatment at 12 months.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.

Saira A. Jan, MS, PharmD, discussed a novel pilot program in New Jersey aiming to expand home infusion services in oncology.

The fast pace of information can make it difficult to efficiently apply data to care.

Subcutaneous nivolumab had demonstrated noninferiority of Cavgd28, Cminss, and ORR compared to the intravenous form of treatment.

The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.

Timothy O’Shea, MS, PharmD, discussed the growth of home infusion programs and how they benefit patients.

Integrating immunotherapies will continue to improve patient outcomes and quality of life.

This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.

A panel hosted by HOPA, ACCC, and AVAHO discusses strategies to ensure patient access to treatment.

This patient population has had low survival rates with available treatments.

PLCOm2012 uses additional parameters to predict the risk of lung cancer and was found more effective when identifying both Indigenous and non-Indigenous individuals with lung cancer.

Kimberly Westrich, MA, discussed value assessment tools and how they can help make key decisions in health care spending.

Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.

Mental health treatment may be necessary when SAEs occur.

In clinical trials, nivolumab (Opdivo) demonstrated a statistically significant improvement in recurrence-free survival compared to placebo in eligible patients with stages IIB, IIC, III, and stage IV completely resected melanoma.

AI systems can detect minute anomalies often missed by the human eye, reducing false negatives.

Trial data bolster the role of nivolumab and nivolumab-based combinations in both early and metastatic stages of multiple cancer types, especially in patient groups with high unmet needs.

TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of the EGFR signaling pathway.

Karline Peal, MBA of Vanderbilt Ingram Cancer Center discusses the positive impact technology has had in health care and how it can be implemented in the future.

Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.

The president of HOPA discusses the importance of mentorship in oncology pharmacy as well as the value of HOPA’s mentorship initiatives.

Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.

Collaboration between AI-based platforms and health care organizations offers promising results.